High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?
Innovation Center China of AstraZeneca Research & Development, Shanghai, China.
Xin
X
Ye
Zhong-Zheng
ZZ
Zhu
Lei
L
Zhong
Yachao
Y
Lu
Yun
Y
Sun
Xiaolu
X
Yin
Zhenfan
Z
Yang
Guanshan
G
Zhu
Qunsheng
Q
Ji
D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D003951:Diagnostic Errors; D066246:ErbB Receptors / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D009154:Mutation / Q000235:genetics*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors